FIZE Medical is a medical-technology company that builds AI-enabled, real‑time urine‑output and fluid‑management systems for hospitals to improve kidney‑care and detect acute kidney injury earlier than manual measurement allows[2][1].
High-Level Overview
- FIZE Medical’s flagship offering is the FIZE kUO platform — a bedside device plus disposable kit that continuously measures urine output from indwelling Foley catheters, streams minute‑by‑minute data into the EMR, and applies proprietary AI to support fluid management and early AKI detection[2][1].- The product is used by hospitals (ICU, surgery, cardiology, pediatrics and other inpatient settings) to replace manual urinometers, save nursing time, and provide clinicians with actionable renal data to guide therapy[2][4].- The platform’s value proposition is earlier, more precise detection of kidney dysfunction (including pediatric sensitivity to small urine changes), operational savings (nursing time, catheter management) and potential reductions in hospital‑acquired AKI and related mortality[2][1][5].- FIZE Medical is a commercial‑stage company founded in 2014 and has raised venture capital (CB Insights reports total funding ~$21.3M and recent raises), while expanding into the U.S., EU and Asian markets and preparing AI predictive features and further product capabilities[1][2].
Origin Story
- FIZE Medical was founded after a chance conversation between Noam Levine — an expert in aerodynamic measurement systems who became the company’s founder/CTO — and an ICU chief, who highlighted the clinical need for accurate urine output monitoring; Levine launched the company to create a cost‑effective digital urine output platform[3].- Leadership cited in public materials includes Dror Zerem as CEO and Noam Levine as founder/CTO, and the company progressed from prototype/beta testing toward mass production and clinical validation during its early years[4][3].- Early pivotal moments included clinical usability testing and small clinical trials to demonstrate accuracy and utility, partnerships with group purchasing organizations (GPOs), and procurement by health systems that helped transition the product into commercial deployments[4][2][5].
Core Differentiators
- Continuous, clinical‑grade measurement: Provides minute‑by‑minute urine output rather than intermittent manual reads, enabling trend analysis and small‑volume sensitivity important in pediatrics and critical care[2][5].- EMR integration and real‑time alerts: Data streams to bedside monitors and uploads to electronic medical records, enabling team-wide visibility and clinical decision support integration[1][2].- AI and predictive roadmap: Proprietary algorithms for detecting early signs of kidney dysfunction and planned AI‑driven patient condition predictions and decision‑support features beyond basic monitoring[1][2].- Operational benefits: Designs to save nursing time, streamline catheter management, and support CAUTI (catheter‑associated urinary tract infection) management and other workflow improvements[2].- Regulatory/clinical positioning: Company has advanced to commercial stage, filed patents, and pursued clinical trials and publications to validate clinical thresholds and support guideline adoption[1][4].
Role in the Broader Tech Landscape
- Trend alignment: FIZE sits at the intersection of remote patient monitoring, clinical AI, digital transformation of hospital workflows, and precision organ‑level monitoring — trends accelerating as hospitals seek outcomes and operational efficiency[2][1].- Why timing matters: Rising focus on preventing hospital‑acquired complications (like AKI), increased EMR maturity, and demand for clinician decision support create a receptive market for continuous physiological signals that were previously manual or absent[5][1].- Market forces in their favor: Health systems’ interest in reducing AKI incidence, regulatory/quality incentives, and cost pressures that reward nursing efficiency and reduced length of stay support adoption[2][1].- Ecosystem influence: By making urine output a continuous, digital vital sign, FIZE can change clinician workflows, enable nephrology–ICU collaboration through shared data, and form the data substrate for future predictive algorithms and guideline updates[5][1].
Quick Take & Future Outlook
- Near term: Expect continued commercial roll‑out in U.S. and international hospitals, additional GPO and health‑system contracting, and deployment of AI decision‑support features (predictive AKI alerts and expanded analytics) that the company has publicly planned[1][2].- Medium term: If clinical studies validate predictive thresholds and show outcomes or cost improvements, FIZE could become standard of care for patients with Foley catheters and a data source for broader fluid‑management ecosystems (automated therapy guidance, integration with closed‑loop fluid systems). Success will depend on convincing clinicians and payers with peer‑reviewed evidence and on seamless EMR/device interoperability[4][1].- Risks and headwinds: Adoption depends on demonstrating clear clinical benefit and ROI versus the incumbent manual process, navigating procurement cycles and regulatory/clinical validation, and competing with other monitoring vendors or hospital‑developed solutions[4][1].- Final thought: By digitizing a previously ignored vital sign (urine output) and coupling it with AI, FIZE Medical addresses a tangible clinical blind spot — if their predictive algorithms and outcome evidence materialize, the company could materially shift how hospitals monitor and manage kidney function[2][1].
If you’d like, I can prepare a one‑page investment memo that summarizes funding, commercialization milestones, competitive landscape, and suggested diligence questions (clinical evidence, reimbursement strategy, EMR integrations). Which would be most useful?
